EUVIMEDEUVIMED entdecken
Open Access

Metabolic Blockade of Glycolysis Diminishes Autoreactive CD4 T-Cell Effector Responses in Type 1 Diabetes

Miranda D Chávez, Anna R Mahr, Heather M Wilkins, Hubert M Tse iD

Diabetes · 2026

DOI: 10.2337/db25-1152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, 2026. Verfasst von Miranda D Chávez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Molecular Genetics, and Immunology, University of Kansas Medical Center, Kansas City, KS. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Deoxyglucose, Glycolysis, CD4-Positive T-Lymphocytes. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Science Foundation, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proinflammatory T helper 1 (Th1) CD4 T cells orchestrate β-cell destruction in type 1 diabetes (T1D) by using glycolysis for effector responses. By targeting T-cell metabolism, we may identify novel mechanisms and therapies to effectively delay T cell–mediated autoimmune diseases like T1D. We hypothesized that treatment of prediabetic mice with the glycolysis inhibitor, 2-deoxyglucose (2-DG), during CD4 T-cell activation would diminish proinflammatory Th1 effector responses and delay β-cell destruction. Treatment of prediabetic nonobese diabetic (NOD) mice with 2-DG significantly delayed spontaneous T1D compared with control mice. In addition to suppressing polyclonal T-cell responses in the pancreatic and mesenteric lymph nodes, diminished Th1 effector responses and an increase in anergy was observed in clonal, autoreactive CD4 T cells stimulated with their cognate autoantigen in the presence of 2-DG. A decrease in CD86 expression in antigen-presenting cells treated with 2-DG may partly explain the induction of CD4 T-cell anergy. Peripheral blood mononuclear cells from patients with or without T1D stimulated with α-CD3/α-CD28–containing microbeads exhibited a decrease in IFNG and TBX21 mRNA with 2-DG treatment. Our studies suggest diminishing glycolysis in autoreactive CD4 T cells can decrease Th1 effector responses and promote anergy as a novel strategy to delay autoimmune diabetes. Article Highlights Our goal: limit glycolysis with 2-deoxyglucose (2-DG) in autoreactive CD4 T cells to delay spontaneous type 1 diabetes in NOD mice. Inhibition of glycolysis with 2-DG during autoreactive CD4 T-cell activation and differentiation decreased effector responses (interferon-γ), increased anergic markers (CD73, folate receptor 4), and delayed spontaneous type 1 diabetes in NOD mice. The effects of 2-DG on antigen-presenting cells resulted in a decrease in CD86 expression that may partly explain the induction of anergy. Inhibiting glycolysis is sufficient to diminish autoreactive CD4 T-cell responses and may be therapeutically applicable to other T cell–mediated inflammatory diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1DeoxyglucoseGlycolysisCD4-Positive T-LymphocytesTh1 CellsAnimalsMice, Inbred NODMiceFemaleHumansInterferon-gammaLymphocyte Activation

Substanzen

DeoxyglucoseInterferon-gamma

Autor:innen und Institutionen

  • Department of Microbiology, Molecular Genetics, and Immunology, University of Kansas Medical Center, Kansas City, KS.
  • Department of Urology, University of Alabama at Birmingham, Birmingham, AL.
  • Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS.
  • University of Kansas Alzheimer's Disease Research Center, University of Kansas Medical Center, Kansas City, KS.
  • Department of Neurology, University of Kansas Medical Center, Kansas City, KS.

ORCID-Profile: Hubert M Tse

Förderung

  • National Science Foundation
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • NIGMS NIH HHS
  • NIDDK NIH HHS
  • Cell, Molecular, and Developmental Biology T32
  • NCI NIH HHS

Zitieren

APA

Chávez, M. D., Mahr, A. R., Wilkins, H. M., & Tse, H. M. (2026). Metabolic Blockade of Glycolysis Diminishes Autoreactive CD4 T-Cell Effector Responses in Type 1 Diabetes. Diabetes. https://doi.org/10.2337/db25-1152

Vancouver

Chávez MD, Mahr AR, Wilkins HM, Tse HM. Metabolic Blockade of Glycolysis Diminishes Autoreactive CD4 T-Cell Effector Responses in Type 1 Diabetes. Diabetes. 2026. doi:10.2337/db25-1152

BibTeX
@article{Chvez2026,
  author = {Chávez, Miranda D and Mahr, Anna R and Wilkins, Heather M and Tse, Hubert M},
  title = {Metabolic Blockade of Glycolysis Diminishes Autoreactive CD4 T-Cell Effector Responses in Type 1 Diabetes},
  journal = {Diabetes},
  year = {2026},
  doi = {10.2337/db25-1152}
}
Kostenlos starten →